Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| iBio, Inc.IBIO · Entity 6906 | Chief Financial Officer | May 27, 2020 | May 29, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
iBio, Inc.
Report date May 27, 2020 · Filed May 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-27 · Exercise / conversion · Acquired 11,250 · Balance 0 F1: Reflects number of securities beneficially owned following all transactions reported on this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-27 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-05-27 · Sale · Disposed 11,250 · Balance 0 F1: Reflects number of securities beneficially owned following all transactions reported on this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2024-02-20 | Direct | 0 |
Reported balance
After 2020-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-27 · Exercise / conversion · Disposed 11,250 · Balance 0 F2: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1: Reflects number of securities beneficially owned following all transactions reported on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects number of securities beneficially owned following all transactions reported on this Form 4.
F2: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2020 Filed May 29, 2020 16:45 UTC | iBio, Inc. IBIO · Entity 6906 | Exercise / conversionStock Option (right to buy) · Derivative | 11,250 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-20-000520 · doc4_6713.xml · derivative · entry 3 Mullaney James P. · CIK 0001702906 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| May 27, 2020 Filed May 29, 2020 16:45 UTC | iBio, Inc. IBIO · Entity 6906 | SaleCommon Stock | 11,250 | $1.61 | $18,112.50 |
DisclosureSEC source: 0001638599-20-000520 · doc4_6713.xml · nonDerivative · entry 2 Mullaney James P. · CIK 0001702906 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| May 27, 2020 Filed May 29, 2020 16:45 UTC | iBio, Inc. IBIO · Entity 6906 | Exercise / conversionCommon Stock | 11,250 | $0.93 | $10,462.50 |
DisclosureSEC source: 0001638599-20-000520 · doc4_6713.xml · nonDerivative · entry 1 Mullaney James P. · CIK 0001702906 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:26 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 11,250 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000500 · doc4_6062.xml · derivative · entry 2 Mullaney James P. · CIK 0001702906 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:26 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001638599-19-000500 · doc4_6062.xml · derivative · entry 1 Mullaney James P. · CIK 0001702906 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 15,000 shares Expires 2027-03-01 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.